10116 related articles for article (PubMed ID: 1755984)
1. Protein tumor antigens.
Srivastava PK
Curr Opin Immunol; 1991 Oct; 3(5):654-8. PubMed ID: 1755984
[TBL] [Abstract][Full Text] [Related]
2. Defining tumor antigens: mRNA, protein or cytotoxicity?
Lim SH; Periman P; Klug P; Weidanz J; Whitton V; Chiriva-Internati M; Wang Z; Wright S
Trends Immunol; 2002 May; 23(5):236-7; author reply 237-8. PubMed ID: 12102740
[No Abstract] [Full Text] [Related]
3. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
[No Abstract] [Full Text] [Related]
4. Genes coding for tumor-specific rejection antigens.
Boon T; Van den Eynde B; Hirsch H; Moroni C; De Plaen E; van der Bruggen P; De Smet C; Lurquin C; Szikora JP; De Backer O
Cold Spring Harb Symp Quant Biol; 1994; 59():617-22. PubMed ID: 7587121
[No Abstract] [Full Text] [Related]
5. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.
Maryanski JL; Van Snick J; Cerottini JC; Boon T
Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607
[TBL] [Abstract][Full Text] [Related]
7. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.
Bilsborough J; Van Pel A; Uyttenhove C; Boon T; Van den Eynde BJ
J Immunol; 1999 Mar; 162(6):3534-40. PubMed ID: 10092811
[TBL] [Abstract][Full Text] [Related]
8. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
9. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay.
Wölfel T; Van Pel A; De Plaen E; Lurquin C; Maryanski JL; Boon T
Immunogenetics; 1987; 26(3):178-87. PubMed ID: 3114137
[TBL] [Abstract][Full Text] [Related]
10. Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity.
Goodell V; Disis ML
J Immunol Methods; 2005 Apr; 299(1-2):129-38. PubMed ID: 15914197
[TBL] [Abstract][Full Text] [Related]
11. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
12. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.
Uyttenhove C; Maryanski J; Boon T
J Exp Med; 1983 Mar; 157(3):1040-52. PubMed ID: 6187879
[TBL] [Abstract][Full Text] [Related]
13. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.
Van den Eynde B; Lethé B; Van Pel A; De Plaen E; Boon T
J Exp Med; 1991 Jun; 173(6):1373-84. PubMed ID: 1903428
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.
De Plaen E; Lurquin C; Van Pel A; Mariamé B; Szikora JP; Wölfel T; Sibille C; Chomez P; Boon T
Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2274-8. PubMed ID: 3127830
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
16. Immune reactions of the syngeneic host after the intradermal injection of tumor cells and microsomes.
Bertschmann M; Lüscher EF
Adv Exp Med Biol; 1973; 29(0):513-8. PubMed ID: 4212066
[No Abstract] [Full Text] [Related]
17. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
18. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96.
Arnold D; Faath S; Rammensee H; Schild H
J Exp Med; 1995 Sep; 182(3):885-9. PubMed ID: 7650492
[TBL] [Abstract][Full Text] [Related]
19. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.
Dai J; Liu B; Caudill MM; Zheng H; Qiao Y; Podack ER; Li Z
Cancer Immun; 2003 Jan; 3():1. PubMed ID: 12747743
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens.
Van Snick J; Maryanski J; Van Pel A; Parmiani G; Boon T
Eur J Immunol; 1982 Nov; 12(11):905-8. PubMed ID: 6818041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
